Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the stock. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $140.00 to $132.00 in a report on Monday, February 24th. Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Intra-Cellular Therapies currently has an average rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $131.19 on Tuesday. The company has a market cap of $13.95 billion, a P/E ratio of -150.79 and a beta of 0.72. The firm has a 50-day simple moving average of $117.36 and a two-hundred day simple moving average of $92.79. Intra-Cellular Therapies has a 1 year low of $63.30 and a 1 year high of $131.36.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. As a group, equities research analysts expect that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Hedge Funds Weigh In On Intra-Cellular Therapies

A number of large investors have recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Intra-Cellular Therapies in the 4th quarter worth approximately $7,951,000. GF Fund Management CO. LTD. acquired a new stake in Intra-Cellular Therapies in the fourth quarter valued at approximately $186,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Intra-Cellular Therapies by 3.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 335,319 shares of the biopharmaceutical company’s stock worth $28,006,000 after purchasing an additional 12,111 shares during the last quarter. Two Sigma Advisers LP acquired a new position in shares of Intra-Cellular Therapies during the fourth quarter worth $11,966,000. Finally, Two Sigma Investments LP increased its position in shares of Intra-Cellular Therapies by 507.9% during the fourth quarter. Two Sigma Investments LP now owns 142,791 shares of the biopharmaceutical company’s stock worth $11,926,000 after purchasing an additional 119,301 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.